Xenon Pharmaceuticals Inc. is a clinical-stage biotech company pioneering gene therapy, particularly with its product Glybera, which aims to treat a rare lipid disorder with a lasting solution.

Xenon Pharmaceuticals Inc. is making progress in 2025 with promising developments in its clinical-stage endeavors, including advancements in Phase 3 programs for epilepsy and psychiatry.